Published in Health and Medicine Week, December 1st, 2003
U.S. patent #9,180,114, titled "Amplifiable Adeno-Associated Virus (AAV) Packaging Cassettes for the Production of Recombinant AAV Vectors," expands Targeted Genetics' production systems used to manufacture AAV vectors.
Targeted Genetics' leading gene delivery vehicle, AAV, is used to deliver a gene of interest into cells of the patient to impact disease. Targeted Genetics uses AAV technology for its AIDS vaccine, cystic fibrosis, and arthritis product candidates.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.